Jim Cramer, host of Mad Money, recently emphasized the importance of long-term investing, urging investors to focus on the ...

Losing weight can feel like climbing a mountain with no clear path. The one-size-fits-all advice—like “eat less, move ...

You can look at the momentum for some stocks and have a feeling that it's about to end. Others, though, have such strong ...

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.

Half of the websites (49.4%) failed to mention risks including adverse effects, warnings and precautions, and ...

A new analysis finds nearly half of the compounded GLP-1 websites didn’t include information on adverse effects, warnings, ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

Novo NOrdisk (NVO) stock drops as Medicare selects 15 additional Part D drugs including its weight loss drug Wegovy for ...

Ozempic, Zepbound, Wegovy, and other GLP-1 medications have transformed the way we lose weight. People who take them report life-changi ...

GLP-1 drugs like Ozempic became so popular as weight loss drugs that there was a mid-year shortage. These drugs are also ...

The weight-loss succession race is heating up. Here's how biopharma execs talked up those efforts at JPM this week.